Literature DB >> 23138552

[Giant-cell arteritis: update: diagnosis and therapy].

M Schirmer1, C Dejaco, W A Schmidt.   

Abstract

Giant-cell arteritis (GCA) is the most common form of vasculitis in patients over 50 years old. Loss of vision is the most common severe complication but involvement of extracranial arteries including the aorta is more frequent than previously assumed. The role of dendritic and T-cells indicates the presence of an antibody but a clear association with underlying infections has not yet been demonstrated. Even if the inflammation parameters in blood are mostly increased in the diagnosis of GCA, specific laboratory tests for the diagnosis of GCA are not available. Of the imaging procedures ultrasonography, magnetic resonance imaging and (18)F-fluorodeoxyglucose positron emission tomography can be useful to localize and estimate the extent of vascular involvement. Glucocorticoids are still the standard therapy of GCA, whereby the cumulative dose can possibly be reduced by additional methotrexate. In addition acetylsalicylic acid is recommended as prophylaxis against cardiovascular and cerebrovascular events as well as prophylaxis and therapy of accompanying osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23138552     DOI: 10.1007/s00393-012-0983-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  26 in total

Review 1.  Medium- and large-vessel vasculitis.

Authors:  Cornelia M Weyand; Jörg J Goronzy
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

2.  BSR and BHPR guidelines for the management of giant cell arteritis.

Authors:  Bhaskar Dasgupta; Frances A Borg; Nada Hassan; Leslie Alexander; Kevin Barraclough; Brian Bourke; Joan Fulcher; Jane Hollywood; Andrew Hutchings; Pat James; Valerie Kyle; Jennifer Nott; Michael Power; Ash Samanta
Journal:  Rheumatology (Oxford)       Date:  2010-04-05       Impact factor: 7.580

3.  High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery.

Authors:  Thorsten A Bley; Oliver Wieben; Markus Uhl; Jens Thiel; Dieter Schmidt; Mathias Langer
Journal:  AJR Am J Roentgenol       Date:  2005-01       Impact factor: 3.959

Review 4.  Methotrexate treatment in large vessel vasculitis and polymyalgia rheumatica.

Authors:  C M Spies; G-R Burmester; F Buttgereit
Journal:  Clin Exp Rheumatol       Date:  2010-10-28       Impact factor: 4.473

5.  Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis.

Authors:  Christian Beyer; Roland Axmann; Enijad Sahinbegovic; Jörg H Distler; Bernhard Manger; Georg Schett; Jochen Zwerina
Journal:  Ann Rheum Dis       Date:  2011-04-24       Impact factor: 19.103

6.  Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease.

Authors:  A D Wagner; J J Goronzy; C M Weyand
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

7.  Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.

Authors:  Gary S Hoffman; Maria C Cid; Karen E Rendt-Zagar; Peter A Merkel; Cornelia M Weyand; John H Stone; Carlo Salvarani; Weichun Xu; Sudha Visvanathan; Mahboob U Rahman
Journal:  Ann Intern Med       Date:  2007-05-01       Impact factor: 25.391

8.  Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.

Authors:  Anne Proven; Sherine E Gabriel; Carlos Orces; W Michael O'Fallon; Gene G Hunder
Journal:  Arthritis Rheum       Date:  2003-10-15

9.  Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis.

Authors:  W A Schmidt; A Seifert; E Gromnica-Ihle; A Krause; A Natusch
Journal:  Rheumatology (Oxford)       Date:  2008-01       Impact factor: 7.580

10.  Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis.

Authors:  Wei Ma-Krupa; Myung-Shin Jeon; Silvia Spoerl; Thomas F Tedder; Jörg J Goronzy; Cornelia M Weyand
Journal:  J Exp Med       Date:  2004-01-19       Impact factor: 14.307

View more
  1 in total

Review 1.  [Ultrasound in rheumatology. What's new?].

Authors:  W Hartung; W A Schmidt
Journal:  Z Rheumatol       Date:  2013-03       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.